



**PBS INFORMATION:** This product is not listed on the PBS or the National Immunisation Program (NIP).

## PLEASE REVIEW FULL SHINGRIX PRODUCT INFORMATION (PI) BEFORE PRESCRIBING, available at www.gsk.com.au/shingrix or by calling GSK Medical Information on 1800 033 109.

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

This is an educational event targeted at your professional development. In line with Medicines Australia Code of Conduct, partners/family members are not able to attend.

We, GlaxoSmithKline Australia Pty Ltd ABN 47 100 162 481 collect, use and disclose personal information about you so we can perform our business activities and functions. We collect your personal information in order to send you direct marketing material and to contact you regarding activities and products or developments in pharmaceutical treatments which may be of interest to you. We may disclose your personal information to third parties we use in the ordinary operations of our business, including our affiliates and third parties located overseas. If we do not collect your personal information, we may be unable to provide you with all of our services. Our privacy policy can be found at http://au.gsk.com/en-au/privacy-policy/ and contains information about how you may access and correct personal information held by us and how you can complain about a breach of priva-cy and how we will deal with such a complaint. If you require, you may access the information we hold about you by writing to the Privacy Officer, GlaxoSmithKline Australia Pty Ltd. Level 3, 436 Johnston Street, Abbotsford, 3067. PM-AU-SGX-LTR-210003 Date of GSK Approval August 2021.

For information on GSK products or to report an adverse event involving a GSK product, please contact GSK Medical Information on 1800 033 109. Trade marks are owned by or licensed to the GSK group of companies. © 2020 GSK group of companies or its licensor. GlaxoSmithKline Australia Pty Ltd. ABN 47 100 162 481. Melbourne. VIC.



## **SHINGRIX:**

# a new paradigm in shingles prevention

Learn more about herpes zoster and SHINGRIX, a new shingles vaccine now available in Australia for your patients ≥50 years old.

**GSK's portfolio of vaccines** have been helping to protect people from a range of serious diseases for well over 100 years. We are pleased to invite you to an educational meeting which aims to enhance your knowledge of **herpes zoster (shingles) and its prevention with SHINGRIX.** 



Your personal information will be collected and provided to the venue to enable the venue to meet their contact tracing obligations.

### **Meeting Details**

**Date & Time:** 

Venue:

#### **RSVP:**

Please register your attendance to reserve your place at this meeting by completing the registration details below.

## **Agenda**

## **Registration Details**



Please complete the form and send to GSK via



Email



Contact GSK Representative on

Speaker - A/Prof Ben Kwan

## Registration

First name	
Surname	
Practice address	
Contact number	
Contact email	
Please list any dietary requirements	
Selected meeting location	